Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126761002 | 12676100 | 2 | F | 201204 | 20160831 | 20160823 | 20160907 | EXP | PHHY2016MX114374 | NOVARTIS | 4.44 | YR | F | Y | 45.00000 | KG | 20160907 | CN | COUNTRY NOT SPECIFIED | MX |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126761002 | 12676100 | 1 | PS | TRILEPTAL | OXCARBAZEPINE | 1 | Oral | 3 ML, QD | 21014 | 3 | ML | QD | |||||||
| 126761002 | 12676100 | 2 | SS | TRILEPTAL | OXCARBAZEPINE | 1 | Oral | 14 ML, QD (8 MONTHS AGO) | 21014 | 14 | ML | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126761002 | 12676100 | 1 | Seizure |
| 126761002 | 12676100 | 2 | Encephalitis brain stem |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126761002 | 12676100 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126761002 | 12676100 | Lupus-like syndrome | |
| 126761002 | 12676100 | Precocious puberty | |
| 126761002 | 12676100 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126761002 | 12676100 | 1 | 201204 | 0 |